持续跟踪有效应对:Ad5/35 基于平台的JN1血统疫苗开发,以应对不断演变的SARS-CoV-2变种
Soojeong Chang1, Jieun Shin1, Seowoo Park1
1Research & Development Center, Cellid Co. Ltd., Seoul, South Korea.
Journal of medical virology
|February 1, 2025
概括
新的SARS-CoV-2变种如JN.1,KP.2,KP.3和LB.1在全球占主导地位. 针对这些JN.1血统变异的疫苗显示出对进化菌株的关键中和活性.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- SARS-CoV-2 病毒不断演变,导致新变种的出现.
- 现在,JN.1及其子变种 (KP.2,KP.3,LB.1) 是全球占主导地位的菌株.
- 来自BA.2.86的JN.1具有显著的尖端蛋白突变,使其与以前的XBB.等变体区分开来.
研究的目的:
- 评估当前JN.1系疫苗对流行SARS-CoV-2变种的中和能力.
- 为了评估JN.1变种与之前流传的菌株的抗原距离.
- 为了确定针对JN.1亚变体的更新疫苗的疗效.
主要方法:
- 对尖蛋白序列的遗传学分析.
- 使用中和试验结果的抗原地图学.
- 在小鼠模型中评估中和标位.
主要成果:
- 与较早的SARS-CoV-2菌株相比,JN.1血统变异在抗原上是遥远的.
- 在小鼠中,针对XBB.1.5的疫苗对JN.1亚变体的中和性降低.
- 针对JN.1,KP.2,KP.3和LB.1开发的疫苗在小鼠中表现出显著的中和活性.
结论:
- 随着SARS-CoV-2的演变,需要持续开发疫苗,以匹配新出现的变种.
- 针对JN.1变种的更新疫苗对于有效中和至关重要.
- 这项研究强调了监测病毒演变对于公共卫生准备的重要性.
相关概念视频
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Immune Response Against Viral Pathogens
732
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
732
Development of Immunocompetence
282
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
282
Cancer Vaccines
329
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
329
Antigen Processing Pathways
905
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
905
Vaccinations
43.9K
Overview
43.9K


